Cargando…

Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?

Non-alcoholic fatty liver disease (NAFLD) prevalence has increased drastically in recent decades, affecting up to 25% of the world’s population. NAFLD is a spectrum of different diseases that starts with asymptomatic steatosis and continues with development of an inflammatory response called steatoh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin-Grau, Maria, Marrachelli, Vannina G, Monleon, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891675/ https://www.ncbi.nlm.nih.gov/pubmed/35317178 http://dx.doi.org/10.4254/wjh.v14.i2.304

Ejemplares similares

Altered Lipid Moieties and Carbonyls in a Wistar Rat Dietary Model of Subclinical Fatty Liver: Potential Sex-Specific Biomarkers of Early Fatty Liver Disease?
por: Martín-Grau, María, et al.
Publicado: (2023)

Microbiome-metabolome signatures in mice genetically prone to develop dementia, fed a normal or fatty diet
por: Sanguinetti, Elena, et al.
Publicado: (2018)

Sex Dimorphism in the Metabolome of Metabolic Syndrome in Morbidly Obese Individuals
por: Pisoni, Serena, et al.
Publicado: (2022)

Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats
por: Forsgård, Richard A., et al.
Publicado: (2017)

Prognosis Biomarkers of Severe Sepsis and Septic Shock by (1)H NMR Urine Metabolomics in the Intensive Care Unit
por: Garcia-Simon, Monica, et al.
Publicado: (2015)

Genomic and Metabolomic Profile Associated to Microalbuminuria
por: Marrachelli, Vannina G., et al.
Publicado: (2014)

Genomic and Metabolomic Profile Associated to Clustering of Cardio-Metabolic Risk Factors
por: Marrachelli, Vannina G., et al.
Publicado: (2016)

Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease
por: Martin-Grau, Maria, et al.
Publicado: (2023)

Bacterial metabolites trimethylamine N-oxide and butyrate as surrogates of small intestinal bacterial overgrowth in patients with a recent decompensated heart failure
por: Mollar, Anna, et al.
Publicado: (2021)

Healthy lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain
por: Delgado-Velandia, Mario, et al.
Publicado: (2022)

Is non‐alcoholic fatty liver disease a reflection of what we eat or simply how much we eat?
por: Sharp, Kiri P H, et al.
Publicado: (2018)

SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease
por: Mazzolini, Guillermo, et al.
Publicado: (2018)

Cardiovascular risk of metabolically healthy obesity in two european populations: Prevention potential from a metabolomic study
por: Wei, Dongmei, et al.
Publicado: (2023)

Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?
por: Gudan, Anna, et al.
Publicado: (2023)

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles
por: Forsgård, Richard A., et al.
Publicado: (2019)

How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?
por: Mann, Jake P., et al.
Publicado: (2016)

Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease
por: Gagnon, Eloi, et al.
Publicado: (2023)

Ketamine plus Alcohol: What We Know and What We Can Expect about This
por: Kobayashi, Natalia Harumi Correa, et al.
Publicado: (2022)

Knowing What’s Out There: Awareness of Non-Alcoholic Fatty Liver Disease
por: Ghevariya, Vishal, et al.
Publicado: (2014)

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2023)

Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease
por: Lee, Kwang Seob, et al.
Publicado: (2022)

Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease
por: Pekkala, Satu
Publicado: (2023)

Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do
por: Sanchez-Torrijos, Yolanda, et al.
Publicado: (2017)

Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases
por: Safaei, Akram, et al.
Publicado: (2016)

Novel Ultrasonographic Fatty Liver Indicator Can Predict Hepatitis in Children With Non-alcoholic Fatty Liver Disease
por: Liu, Hsien-Kuan, et al.
Publicado: (2019)

Development and characterization of an experimental model of diet-induced metabolic syndrome in rabbit
por: Arias-Mutis, Oscar Julián, et al.
Publicado: (2017)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Jets: what we can still learn....
por: Humpert, Benedikt, et al.
Publicado: (1984)

Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine
por: Shao, Mingmei, et al.
Publicado: (2022)

Long Non-Coding RNA Profiling in a Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight into Pathogenesis
por: Chen, Yi, et al.
Publicado: (2017)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Implementation of HPV Tests in Latin America: What We Learned; What Should We Have Learned, and What Can We Do Better?
por: Godoy, Luani Rezende, et al.
Publicado: (2022)

Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome
por: Moolla, Ahmad, et al.
Publicado: (2020)

Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity
por: Buchard, Benjamin, et al.
Publicado: (2021)

Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)?
por: Merchant, Hamid A.
Publicado: (2017)

Lipoprotein profiles of fat distribution and its association with insulin sensitivity
por: Wei, Dongmei, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Metabolomics in Psychiatric Disorders: What We Learn from Animal Models
por: Humer, Elke, et al.
Publicado: (2020)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mhfb39orbq10qsp9930kpenbht